Table 5.
Sensitivity Analyses by Excluding Subjects With Extreme Lipoprotein(a) Levels or Participants With CVEs Developed During the First Year
| Category | Hazard Ratio (95% CI) | ||
|---|---|---|---|
| Unadjusted Model | Model 1 | Model 2 | |
| Sensitivity analysis 1 | |||
| Lipoprotein(a) per 1‐SD increase | 1.2 (1.0–1.4) | 1.2 (1.0–1.4) | 1.3 (1.1–1.6) |
| Low lipoprotein(a) | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| Medium lipoprotein(a) | 1.2 (0.8–1.7) | 1.1 (0.8–1.7) | 1.2 (0.7–1.8) |
| High lipoprotein(a) | 1.6 (1.1–2.2) | 1.5 (1.1–2.1) | 2.0 (1.4–3.0) |
| Sensitivity analysis 2 | |||
| Lipoprotein(a) per 1‐SD increase | 1.2 (1.0–1.3) | 1.2 (1.0–1.3) | 1.3 (1.1–1.5) |
| Low lipoprotein(a) | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| Medium lipoprotein(a) | 1.2 (0.8–1.8) | 1.1 (0.7–1.7) | 0.9 (0.5–1.6) |
| High lipoprotein(a) | 1.6 (1.1–2.2) | 1.5 (1.1–2.2) | 1.9 (1.3–2.9) |
In sensitivity analysis 1, subjects with lipoprotein(a) levels in the top or the bottom 5% were excluded. In sensitivity analysis 2, participants with CVEs developed during the first year were excluded. CVEs indicates cardiovascular events.